 Package of a days worth of Paxlovid in those with normal kidney function. | |
| Combination of | |
|---|---|
| Nirmatrelvir | Antiviral drug |
| Ritonavir | CYP3A inhibitor |
| Clinical data | |
| Trade names | Paxlovid |
| Other names | Nirmatrelvir/r |
| License data |
|
| Routes of administration | By mouth |
| Legal status | |
| Legal status | |
Nirmatrelvir/ritonavir, sold under the brand name Paxlovid, is two medications packaged together and used to treat COVID-19.[1] It is used within 5 days of the start of symptoms, in people who do not require supplemental oxygen, but are at high risk of developing severe COVID-19.[1][3] It is taken by mouth.[3]
Common side effects include taste disturbances, diarrhea, high blood pressure, and muscle pains.[3] Safety in pregnancy is unclear.[1] It should not be used in people with severe liver or kidney problems.[1] It has a number of medication interactions, including with hormonal birth control.[3][1] It is contains nirmatrelvir, a SARS-CoV-2 main protease inhibitor and ritonavir, a CYP3A inhibitor.[3]
The combination was approved for medical use in the United Kingdom in December of 2021.[1] It also received emergency use authorization in the United States that month.[3] In 2021 the United States government bought 10 million courses of treatment at 530 USD each, which it will be providing at no cost to Americans.[6][7] Approval occurred in the United States in 2023.[8]
References edit
- ^ a b c d e f g h i "Summary of Product Characteristics for Paxlovid". Medicines and Healthcare products Regulatory Agency (MHRA). 31 December 2021. Archived from the original on 31 December 2021. Retrieved 31 December 2021.
- ^ "Regulatory approval of Paxlovid". Medicines and Healthcare products Regulatory Agency (MHRA). 31 December 2021. Archived from the original on 11 January 2022. Retrieved 31 December 2021.
- ^ a b c d e f g h i j "Paxlovid- nirmatrelvir and ritonavir kit". DailyMed. Archived from the original on 31 December 2021. Retrieved 30 December 2021.
- ^ "FDA Authorizes First Oral Antiviral for Treatment of COVID-19". U.S. Food and Drug Administration (FDA) (Press release). 22 December 2021. Archived from the original on 27 December 2021. Retrieved 22 December 2021.
This article incorporates text from this source, which is in the public domain.
- ^ Fact sheet for healthcare providers: Emergency Use Authorization for Paxlovid (PDF) (Technical report). Pfizer. 22 December 2021. LAB-1492-0.8. Archived from the original on 23 December 2021.
- ^ "U.S. to buy 10 mln courses of Pfizer's COVID-19 pill for $5.3 bln". Reuters. 18 November 2021. Archived from the original on 3 January 2022. Retrieved 6 January 2022.
- ^ "FDA Grants Pfizer's COVID Antiviral Pill EUA - GoodRx". GoodRx. Archived from the original on 31 December 2021. Retrieved 6 January 2022.
- ^ Research, Center for Drug Evaluation and (14 August 2023). "Novel Drug Approvals for 2023". FDA. Archived from the original on 21 January 2023. Retrieved 15 August 2023.
